114/06/03 19:30 - 20:30

-

線上課程

時段	主題	講師	主持人
19:30~20:30	The Transforming Role of SGLT2 Inhibitors for Kidney	廖國盟 醫師

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have revolutionized the treatment landscape of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Initially developed as glucose-lowering agents, SGLT2i have demonstrated remarkable renoprotective benefits beyond glycemic control, making them a cornerstone therapy for kidney protection in diabetic and non-diabetic patients. Renal Protection Beyond Glucose Control SGLT2i exert multiple beneficial effects on the kidneys, primarily through reducing intraglomerular pressure and mitigating hyperfiltration, key drivers of CKD progression. By inhibiting glucose and sodium reabsorption in the proximal tubules, these agents restore tubuloglomerular feedback, leading to afferent arteriole constriction and a reduction in glomerular pressure. This mechanism translates into reduced albuminuria, slower decline in estimated glomerular filtration rate (eGFR), and delayed onset of end-stage kidney disease (ESKD). Evidence from Landmark Clinical Trials Major clinical trials, including CREDENCE, DAPA-CKD, and EMPA-KIDNEY, have confirmed the robust kidney benefits of SGLT2i. These studies demonstrated that canagliflozin, dapagliflozin, and empagliflozin significantly lower the risk of CKD progression, dialysis initiation, and cardiovascular events. Notably, these benefits extend to patients without diabetes, reinforcing the role of SGLT2i as a kidney-specific therapy rather than solely a glucose-lowering agent. Cardiorenal Benefits and Mortality Reduction Beyond kidney protection, SGLT2i have profound effects on heart failure and cardiovascular mortality. They reduce the risk of heart failure hospitalization and major adverse cardiovascular events (MACE), making them an essential component of cardiorenal-metabolic (CKM) management. This paradigm shift has positioned SGLT2i as first-line therapy in CKD guidelines, independent of diabetes status. Expanding Indications and Future Directions The evolving role of SGLT2i continues to expand, with ongoing research exploring their anti-inflammatory, antifibrotic, and metabolic benefits. Future studies will likely establish their role in non-diabetic kidney disease, acute kidney injury prevention, and combination therapy with other renoprotective agents such as mineralocorticoid receptor antagonists (MRAs) and GLP-1 receptor agonists. Conclusion SGLT2 inhibitors have transformed the management of CKD, offering a powerful tool for kidney and cardiovascular protection. Their ability to delay dialysis, reduce mortality, and improve long-term renal outcomes underscores their role as a cornerstone therapy in nephrology and metabolic medicine. As we embrace this new era of renal protection, SGLT2i represent a paradigm shift towards holistic, multi-organ management in CKD.

線上課程

-

-

社團法人中華民國藥師公會全國聯合會專業1.2積分
中華民國糖尿病學會乙類0.5分
社團法人中華民國糖尿病衛教學會乙類1分
台灣內科醫學會B類 1分
家醫計畫2.0時數：DKD 1小時
《實際學分數以各醫學會實際通過為主，包含審查中之各醫學會學分》